A set of ~800 largely isogenic deficiency stocks created by FLP-induced recombination between FRT-carrying transgenic insertions; molecularly defined deletion endpoints correspond to initial location of the progenitor insertions. Designed to fill gaps in deletion coverage and breakpoint placement; also used to replace older available deficiencies that have not been molecularly mapped.
Inferred to overlap with: Df(2R)BSC313.
The presence of P+PBac{XP5.WH5}BSC889 was verified using the PCR methods and primers described in FBrf0175003.
Exelixis, Inc. determined the insertion site of PBac{WH}CG11211f02744 to be Release 3 genomic coordinate 2R:1320210 . This corresponds to 2R:2069250 on the Release 5 genome map.
The breakpoints of Df(2R)BSC889 predicted from the Release 5 genomic coordinates of the progenitor P{XP}CG11163d05998 and PBac{WH}CG11211f02744 transposable element insertion sites are 2R:1669744--1669934 ;2069250 and the cytological breakpoints predicted from these coordinates are 41F11;42A13.